Aspire Biopharma Holdings (ASBP) Shares Outstanding (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Shares Outstanding (Entity) of $167470.0 for Q1 2026, up 430.39% year-over-year from $31575.0 in Q1 2025, and up 236.07% quarter-over-quarter from $49832.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Shares Outstanding (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Shares Outstanding (Entity) for 6 consecutive years, with $167470.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 430.39% year-over-year to $167470.0; the TTM figure through Mar 2026 stood at $167470.0 (up 430.39% YoY), while the FY2025 annual figure was $49832.0, down 88.21% from the prior year.
- Shares Outstanding (Entity) rose to $167470.0 in Q1 2026 per ASBP's latest filing, from $49832.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $422795.0 in Q4 2024 and bottomed at $5990.0 in Q2 2024.
- Historically, Shares Outstanding (Entity) has averaged $53529.5 across 5 years, with a median of $23958.0 in 2022.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) soared 2982.05% — and 2025, when it sank 88.21%.
- Aspire Biopharma Holdings' Shares Outstanding (Entity) stood at $20414.0 in 2022, then sank by 32.8% to $13718.0 in 2023, then jumped by 2982.05% to $422795.0 in 2024, then tumbled by 88.21% to $49832.0 in 2025, then surged by 236.07% to $167470.0 in 2026.
- Business Quant data shows ASBP's Shares Outstanding (Entity) at $167470.0 in Q1 2026, $49832.0 in Q4 2025, and $41272.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Mn |
| Mar 31, 2026 | 156,685.00 |
| Dec 31, 2025 | 49,832.00 |
| Sep 30, 2025 | 41,272.00 |
| Jun 30, 2025 | 41,111.00 |
| Mar 31, 2025 | 31,575.00 |
| Dec 31, 2024 | 422,795.00 |
| Sep 30, 2024 | 6,471.00 |
| Jun 30, 2024 | 7,055.00 |
| Mar 31, 2024 | 7,493.00 |
| Dec 31, 2023 | 13,718.00 |
| Sep 30, 2023 | 7,493.00 |
| Jun 30, 2023 | 13,230.00 |
| Mar 31, 2023 | 23,958.00 |
| Dec 31, 2022 | 20,414.00 |
| Sep 30, 2022 | 23,958.00 |
| Jun 30, 2022 | 23,958.00 |
| Mar 31, 2022 | 9,583.00 |
| Dec 31, 2021 | 5,208.00 |
| Sep 30, 2021 | 5,208.00 |